Objective: The 21-gene recurrence score (RS) assay has been widely adopted for use in early estrogen receptor (ER)-positive breast cancer to assess the risk for distant recurrence and the potential benefit of adjuvant chemotherapy. The primary aim of this study was to assess RS distribution in Israeli male breast cancer (MBC) patients. Methods: The study population included 65 newly diagnosed Israeli MBC patients. Clinical and pathologic data were collected at the time of referral. Pathologic examinations were conducted at the pathology departments of the referring centers. The RS assay (Oncotype DX™) was performed on paraffin-embedded tumor samples at Genomic Health laboratories. Results: The mean age of the patients was 65.1 years (range 38-88 years). Low-risk (RS <18), intermediate-risk (RS 18-30) and high-risk (RS ≥31) scores were noted in 29 patients (44.6%), 27 patients (41.5%) and 9 patients (13.9%), respectively. The distribution of RS in male patients was similar to the distribution in 2,455 female patients from Israel referred during the same time period. Conclusion: Our data suggest that the distribution of Oncotype DX RS in ER-positive MBC patients is similar to that of female breast cancer patients.

Fentiman IS, Fourquet A, Hortobagyi GN: Male breast cancer. Lancet 2006;367:595-604.
Sasco AJ, Lowenfels AB, Pasker-de Jong J: Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993;53:538-549.
Anderson WF, Althuis MD, Brinton LA, Devesa SS: Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004;83:77-86.
Grenader T, Goldberg A, Shavit L: Second cancers in patients with male breast cancer: a literature review. J Cancer Surviv 2008;2:73-78.
Korde LA, Zujewski JA, Kamin L, et al: Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010;28:2114-2122.
Rudlowski C, Friedrichs N, Faridi A, et al: Her2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004;84:215-223.
Kornegoor R, Verschuur-Maes AH, Buerger H, et al: Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 2012;25:398-404.
Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
Albain KS, Barlow WE, Shak S, et al; Breast Cancer Intergroup of North America: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
Liebermann N, Klang SH, Soussan-Gutman L, et al: Evaluation of recurrence score, nodal status and traditional clinicopathologic metrics in a large ER positive patient cohort. Eur J Cancer 2011;47(suppl 1):S175 (abstract 1420).
Giordano SH, Perkins GH, Broglio K, et al: Adjuvant systemic therapy for male breast carcinoma. Cancer 2005;104:2359-2364.
Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ: An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 1999;126:775-780.
Eggemann H, Ignatov A, Smith BJ, et al: Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 2013;137:465-470.
Shak S, Palmer G, Baehner FL, et al: Molecular characterization of male breast cancer by standard quantitative RT-PCR analysis: first large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol 2009;27(suppl 15S):18s (abstract 549).
Callari M, Cappelletti V, De Cecco L, et al: Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 2011;127:601-610.
Johansson I, Nilsson C, Berglund P, et al: Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 2012;14:R31.
Chodick G, Struewing JP, Ron E, et al: Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and Non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999. Eur J Med Genet 2008;51:141-147.
Deb S, Jene N, kConFab investigators, Fox SB: Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer 2012;12:510.
Rennert G, Bisland-Naggan S, Barnett-Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:115-123.
Burstein HJ, Harris JR, Morrow M: Malignant tumors of the breast; in DeVita VT Jr, Lawrence TS, Rosenberg SA (eds): Cancer Principles & Practice of Oncology, ed 9. Philadelphia, Lippincott Williams & Wilkins, 2011, p 1438.
Dowsett M, Cuzick J, Wale C, et al: Prediction of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829-1834.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.